glargine
- Generic Name
- glargine
SITAgliptin Plus GLARgine to Glycemic Control in the Hospital Setting (SITAGLAR-H)
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Hospital de Especialidades, Centro Medico Nacional "La Raza", Instituto Mexicano del Seguro Social
- Target Recruit Count
- 76
- Registration Number
- NCT05579119
- Locations
- 🇲🇽
División de Investigación en Salud, Hospital de Especialidades, Centro Médico Nacional "La Raza", IMSS, Mexico City, Mexico
Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 Diabetes
- Conditions
- Coronary Artery DiseaseType2diabetes
- Interventions
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Medanta, The Medicity, India
- Target Recruit Count
- 250
- Registration Number
- NCT05457933
- Locations
- 🇮🇳
Division Of Endocrinology and Diabetes, Medanta The Medicity, Gurgaon, Haryana, India
Outcome of Glargine Insulin in Renal Impairment Patients With Diabetic Ketoacidosis
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2022-06-07
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 52
- Registration Number
- NCT05219942
- Locations
- 🇪🇬
Ain Shams University, Cairo, Egypt
Intermediate and Long Acting Insulin Young Children Type 1 Diabetes.
- Conditions
- Type 1 Diabetes Mellitus With Hypoglycemiatype1diabetes
- Interventions
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 60
- Registration Number
- NCT04664764
- Locations
- 🇪🇬
Ain Shams University, Cairo, Egypt
Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT03829891
- Locations
- 🇨🇳
Chang'an Hospital, Xi'an, China,Shanxi, China
🇨🇳Shaanxi Aerospace Hospital, Xi'an, China,Shanxi, China
Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables
- Conditions
- Diabetes Mellitus
- Interventions
- First Posted Date
- 2019-01-31
- Last Posted Date
- 2019-01-31
- Lead Sponsor
- University of Palermo
- Target Recruit Count
- 92
- Registration Number
- NCT03824002
- Locations
- 🇮🇹
Internal Medicine Ward, University of Palermo, Palermo, Italy
Remission Through Early Monitored Insulin Therapy - Duration Month
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2018-09-13
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Sandra Sobel
- Target Recruit Count
- 10
- Registration Number
- NCT03670641
- Locations
- 🇺🇸
UPMC Falk Diabetes Clinic, Pittsburgh, Pennsylvania, United States
Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia
- Conditions
- Hyperglycemia Steroid-inducedInsulin Resistance, Diabetes
- Interventions
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2020-09-11
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 3
- Registration Number
- NCT03511521
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes
- First Posted Date
- 2017-11-08
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Emory University
- Target Recruit Count
- 180
- Registration Number
- NCT03336528
- Locations
- 🇺🇸
Emory University Hospital Clinical Research Network, Atlanta, Georgia, United States
🇺🇸Grady Hospital, Atlanta, Georgia, United States
🇺🇸Mount Sinai, New York, New York, United States
Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes
- Conditions
- Diabetic KetoacidosisType 1 Diabetes Mellitus
- Interventions
- Device: Continuous Glucose Monitor (Abbott FreeStyle Libre Pro)
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 61
- Registration Number
- NCT03107208
- Locations
- 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.